Clinical Trial Search

Primary: The Change From Baseline as Assessed on the Investigator's Global Assessment (IGA) Score. — -0.8; -1.0; -0.6; -0.8 score on a scale — p=0.022

Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue (30 Minutes), and From Test Day 1 Through Test Day 4 (1 Week)) - Via the Visual Analog Scale for…

Primary: Central Corneal Thickness (CCT) — -28.4; -20.1 µm — p=0.0021

Primary: Time to Discontinuation Due to Adverse Event (AE) — 93.02; 116.86 days — p=0.184

Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — 58.95; 57.21; -18.80; -16.60 units on a scale

Primary: Maximally Tolerated Dose (MTD) (Phase 1b) — NA mg/m^2

Primary: Gastrointestinal (GI) Tolerability Score — 2.31; 2.63; 2.70; 2.71 score on a scale

Primary: Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments — 47.8 percentage of confirmed responses

Primary: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) — -13.72; -15.11; -14.38 score on a scale

Primary: Change in Affective Reactivity Index - Youth (ARI-Y) — -2.9; -0.8 score on a scale

Primary: Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication — 106 Participants

Primary: Overall Response Rate (ORR) — 6; 0 Participants

Primary: Clinical Benefit Rate (CBR) [Phase 2a] — 6 Participants

Primary: Phase 1: Number of Participants With Dose-limiting Toxicities — 0; 1 Participants

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6 for AD Participants — -35.5; -74.9 Percent Change — p=0.0004